Begin main content

Pembrolizumab (Keytruda) classical Hodgkin Lymphoma – Details

Project Number pCODR 10109
Brand Name Keytruda
Generic Name Pembrolizumab
Tumour Type Lymphoma and Myeloma
Indication classical Hodgkin Lymphoma (cHL)
Funding Request For patients with classical Hodgkin Lymphoma (cHL) who failed to achieve a response or progressed after ASCT and have relapsed after treatment with or failed to respond to brentuximab vedotin post ASCT; or who did not receive an ASCT and have relapsed after treatment with or failed to respond to brentuximab vedotin; or who failed to respond to or progressed after ASCT and have not received brentuximab vedotin post ASCT
Review Status Under Review
Pre Noc Submission Yes
NOC Date
Manufacturer Merck Canada Inc.
Submitter Merck Canada Inc.
Submission Date July 7, 2017
Submission Deemed Complete July 14, 2017
Submission Type New Indication
Prioritization Requested Requested and Granted
Stakeholder Input Deadline ‡ July 21, 2017
Check-point meeting September 6, 2017
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.